Eosinophilic Esophagitis Clinical Trial
Official title:
COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS)
Therapeutic strategies for eosinophilic esophagitis (EoE) actually include: 1) allergen
avoidance through dietary modifications, and 2) pharmacologic antiinflammatory therapy.
Medical treatment is mainly based on topical administration of corticosteroids by swallowing
fluticasone propionate or budesonide spray. Dietetic treatment with highest efficacy is
elemental diet, consisting in exclusive feeding with amino-acid based formulas, often
administered trough SNG. Alternative choices of acceptable efficacy are empirical six-foods
elimination diet (cow's milk, egg, soy, wheat, peanuts, fish) and targeted elimination diet
based on the results of allergy tests. Most of the paediatric patients with EE respond to
elemental or targeted elimination diets, and therefore such authors recommend elimination
diets to be considered the treatment of choice in children. However, elimination diets can
often be complex to follow and may be associated with poor adherence owing to the low
palatability of a highly restricted diet. In non-compliant patients, especially in
adolescents and young adults, it may be more practical to proceed first with corticosteroid
treatment. In the case of partial response to elimination diets or corticosteroids, a
combination of both treatment mod. However, there has been limited testing of these regimens
in randomized controlled trials, while most of available literature is based on case series.
The aim of this study was to compare the efficacy of six-foods elimination diet, swallowed
fluticasone, swallowed budesonide and oral viscous budesonide (OVB) in pediatric patients
with active EoE. The investigators assessed the effects of randomly assigned treatment on
clinical and endoscopic/histologic severity as primary and secondary outcomes, respectively.
The investigators describe clinical, allergological, endoscopic and histological features,
and pH study results, of our pediatric population.
Eosinophilic esophagitis (EoE) is characterized by significant eosinophilic infiltration of esophageal mucosa, leading to tissue damage and consequently to esophageal symptoms. The clinical presentation in childhood often mimics gastro-esophageal reflux disease (GERD), sometimes in association to feeding difficulties and failure to thrive. Later in life, the most common symptoms are dysphagia and food impaction, due to esophageal dysmotility. The progression of a non-recognized, untreated disease, is thought to lead to chronic esophageal inflammation with fibrosis and stenosis. Diagnosis requires multiple esophageal biopsies (at least 4 in both proximal and distal esophagus, regardless of gross appearance of mucosa) to demonstrate a mucosal infiltrate of at least 15 eosinophils for high power field (HPF) in patients with a normal pH study or refractory to acid-suppression therapy. Although the endoscopic examination may be unremarkable, endoscopic features of EoE have been well characterized and include: linear furrowing, concentric rings (thachealization), white spots (eosinophilic abscesses), Schatzki ring, strictures, and linear superficial mucosal tears occurring after introduction of the endoscope. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03382678 -
CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry
|
||
Completed |
NCT05083312 -
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
|
Phase 3 | |
Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
Completed |
NCT03633617 -
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
|
Phase 3 | |
Completed |
NCT04941742 -
The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Validation Phase)
|
||
Terminated |
NCT04543409 -
A Study of Benralizumab in Patients With Eosinophilic Esophagitis
|
Phase 3 | |
Terminated |
NCT02314455 -
Esophageal Absorption in EoE
|
N/A | |
Completed |
NCT01953575 -
Mucosal Impedance and Eosinophilic Esophagitis
|
N/A | |
Completed |
NCT01386112 -
Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04991935 -
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
|
Phase 3 | |
Not yet recruiting |
NCT05896891 -
San Raffaele EoE Biobank
|
||
Active, not recruiting |
NCT05482256 -
A Study of Detergents in the Pathogenesis of Eosinophilic Esophagitis
|
N/A | |
Recruiting |
NCT05485155 -
Zemaira Eosinophilic Esophagitis Pilot Study
|
Phase 2 | |
Recruiting |
NCT04149470 -
Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
|
Phase 4 | |
Recruiting |
NCT04416217 -
Eosinophilic Esophagitis Steroid Safety Study
|
||
Completed |
NCT05084963 -
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
|
Phase 2 | |
Completed |
NCT02579876 -
Milk Patch for Eosinophilic Esophagitis
|
Phase 2 | |
Recruiting |
NCT02331849 -
Esophageal Motility in Eosinophilic Esophagitis Evaluated by High Resolution Manometry.
|
N/A | |
Active, not recruiting |
NCT02202590 -
Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus
|
N/A | |
Active, not recruiting |
NCT05176249 -
Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population
|